<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03805841</url>
  </required_header>
  <id_info>
    <org_study_id>RAIN-701</org_study_id>
    <nct_id>NCT03805841</nct_id>
  </id_info>
  <brief_title>Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) &amp; Other Solid Tumors With NRG1/ERBB Gene Fusions</brief_title>
  <acronym>RAIN</acronym>
  <official_title>Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rain Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rain Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, Phase 2, single treatment arm, 3 cohorts&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    enrollment pause&#xD;
  </why_stopped>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Actual">April 23, 2021</completion_date>
  <primary_completion_date type="Actual">April 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>through study completion, an average of 10 months</time_frame>
    <description>Objective Response Rate (number of subjects with PR or CR)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>NSCLC, Stage IV</condition>
  <condition>NSCLC Stage IIIB</condition>
  <condition>NSCLC, Stage IIIC</condition>
  <condition>NSCLC, Recurrent</condition>
  <condition>EGFR Exon 20 Insertion Mutation</condition>
  <condition>HER2-activating Mutation</condition>
  <condition>ERBB Fusion</condition>
  <condition>NRG1 Fusion</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tarloxotinib bromide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tarloxotinib bromide</intervention_name>
    <description>weekly intravenous infusion</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Tarlox</other_name>
    <other_name>tarloxotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically and/or cytologically confirmed primary diagnosis of NSCLC, Stage IV,&#xD;
             Stage IIIB or IIIC not amenable to definitive curative intent therapy, or recurrent&#xD;
             disease after prior diagnosis of Stage I-III disease. Cohort C locally advanced or&#xD;
             metastatic solid tumor.&#xD;
&#xD;
          -  Progression of disease on or after a platinum-based chemotherapy regimen (Cohorts A&#xD;
             and B) or after standard of care (Cohort C)&#xD;
&#xD;
          -  EGFR exon 20 insertion mutation (Cohort A) or HER2 activating mutation (Cohort B) or&#xD;
             NRG1 or ERBB family gene fusions (Cohort C)&#xD;
&#xD;
          -  Measurable disease according to RECIST v.1.1&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN (or calculated creatinine clearance ≥ 60 mL/min using&#xD;
             Cockcroft Gault equation)&#xD;
&#xD;
          -  Total bilirubin: ≤ 1.5 x ULN or ≤ 3 x ULN in the presence of liver metastases&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or ≤&#xD;
             5 x ULN, in the presence of liver metastases&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1,500 cells/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL or 5.6 mmol/L&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  No evidence of second or third degree atrioventricular block&#xD;
&#xD;
          -  No clinically significant arrhythmia (i.e.; pauses of &gt; 4 seconds, VT of any duration,&#xD;
             SVT &gt; 4 beats/minute)&#xD;
&#xD;
          -  QRS interval ≤ 110 ms&#xD;
&#xD;
          -  QTcF interval of &lt; 450 ms&#xD;
&#xD;
          -  PR interval ≤ 200 ms&#xD;
&#xD;
          -  Adequate pretreatment tumor sample (125 µm of FFPE block or at least 8 prepared&#xD;
             slides)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Another known activating oncogene driver mutation&#xD;
&#xD;
          -  (Cohorts A and B Only) Previously received anti EGFR or anti HER2 tyrosine kinase&#xD;
             inhibitors&#xD;
&#xD;
          -  (Cohorts A and B Only) Previously received anti EGFR or anti HER2 monoclonal&#xD;
             antibodies or EGFR or HER2 antibody drug conjugates&#xD;
&#xD;
          -  Investigational therapy administered within the 28 days or 5 half lives&#xD;
&#xD;
          -  Chemotherapy or radiation within 14 days prior to Cycle 1 Day 1&#xD;
&#xD;
          -  Immunotherapy within 21 days&#xD;
&#xD;
          -  Clinically active or symptomatic interstitial lung disease (ILD) or interstitial&#xD;
             pneumonitis, or a history of clinically significant ILD or radiation pneumonitis&#xD;
&#xD;
          -  Untreated and/or symptomatic CNS malignancies (primary or metastatic);&#xD;
&#xD;
          -  Receiving medication that prolongs QT interval, with a risk of causing Torsade de&#xD;
             Pointes (TdP)&#xD;
&#xD;
          -  Personal or familial history of Long QT Syndrome&#xD;
&#xD;
          -  NYHA class III or IV or LVEF &lt; 55%&#xD;
&#xD;
          -  Myocardial infarction, severe or unstable angina within 6 months&#xD;
&#xD;
          -  History of TdP, ventricular arrhythmia&#xD;
&#xD;
          -  Significant thrombotic or embolic events within 3 months&#xD;
&#xD;
          -  Uncontrolled or severe cardiovascular disease&#xD;
&#xD;
          -  Concurrent malignancy expected to require treatment within 2 years or interfere with&#xD;
             study outcomes&#xD;
&#xD;
          -  History of severe allergic reactions or hypersensitivity to compounds of similar&#xD;
             chemical or biologic composition as tarloxotinib&#xD;
&#xD;
          -  Known HIV infection or active Hepatitis B or C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen V Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RAIN-701 Study Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco, Helen Diller Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAIN-701 Study Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Care and Research Center, Atlanta</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAIN-701 Study Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAIN-701 Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAIN-701 Study Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAIN-701 Study Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hong Kong United Oncology Center</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No Plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

